The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran.
Xarelto is the first once-a-day alternative to warfarin and does not require the regular blood testing that warfarin does. Learn more about the approval of Xarelto at:
Xarelto Approved by the FDA for Atrial Fibrillation Stroke Prevention
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.
Add a Comment1 Comments
That's great news! Thanks for sharing :)
November 7, 2011 - 8:33amThis Comment